

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28435 A1

- (51) International Patent Classification⁷: **A61K 47/10**, A61P 17/10
- (74) Agent: **WATERMARK PATENT & TRADEMARK ATTORNEYS**; 290 Burwood Road, Hawthorn, VIC 3122 (AU).
- (21) International Application Number: PCT/AU01/01237
- (22) International Filing Date: 2 October 2001 (02.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PRO486 2 October 2000 (02.10.2000) AU
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **SOLTEC RESEARCH PTY LTD.** [AU/AU]; 8 Macro Court, Rowville, VIC 3178 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **ABRAM, Albert** [US/US]; 3 Abbey Court, Wantima, VIC 3152 (US). **HOULDEN, Robert** [AU/AU]; 7 Colesbourne Court, Kilsyth, VIC 3137 (AU). **PIRZAS, Vicky** [AU/AU]; 13 Gay Street, Blackburn North, VIC 3130 (AU).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/28435 A1

(54) Title: **PHARMACEUTICAL VEHICLE**

(57) Abstract: This invention relates to vehicles for the percutaneous delivery of at least one pharmaceutically active agent to the epidermis. In particular this invention relates to pharmaceutical compositions directed to the treatment of skin diseases, more particularly those containing salicylic acid. More specifically, a hydroalcoholic vehicle for percutaneous delivery of an active agent to the epidermis, said vehicle comprising lower alcohol, water and wax-surfactant, said wax surfactant being one, or a combination of compounds selected from the group consisting of acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyl dibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. The invention further relates to methods of treatment of skin diseases, more particularly acne.

Best Available Copy

PHARMACEUTICAL VEHICLE

FIELD OF THE INVENTION

This invention relates to vehicles for the percutaneous delivery of at least one pharmaceutically active agent to the epidermis. In particular this invention
5 relates to pharmaceutical compositions directed to the treatment of skin diseases, more particularly those containing salicylic acid.

BACKGROUND

Pharmaceutical active agents commonly used to treat acne and other skin diseases include but are not limited to the therapeutic substances salicylic acid,
10 isotretinoin, benzoyl peroxide, resorcinol, non-steroidal anti-inflammatory drugs such as ketoprofen, corticosteroids such as cortisone, antifungals, antibiotics for microbial infections and anti-psoriatics such as etrinate. It is common to also include other substances such as anaesthetics, for example lignocaine where necessary. Treatment of acne is traditionally effected by external, topical
15 application of a pharmaceutical substance. Where this is ineffective, systemic treatments such as by hormone treatment can be utilised but do have undesirable side effects in some patients. Salicylic acid is one well recognized anti-acne active agent which causes a reduction in intercellular cohesion of individual dead skin cells which are the starting point of acne infection. Ideally an anti acne
20 pharmaceutical should maximise penetration of the active agent through the upper layers of the epidermis and should assist in optimising the levels of active agent retained in the epidermis without allowing penetration of the active agent into the patient's system

The challenge in applying a pharmaceutical topically is to achieve
25 percutaneous penetration of the active agent to the site of treatment, in many cases the epidermis. At the same time it is important that the composition have desirable cosmetic characteristics. Application should be easy, smooth and should result in no irritation, discomfort or inconvenience. Desirably the composition should not leave a residue on the surface of the skin, oily or
30 otherwise. Active agents can be applied in various vehicles such as liquid preparations, mousses, gels, ointments, lotions, creams and pastes. Such compositions are often very viscous requiring substantial rubbing to achieve penetration of the active agent to the affected skin layer, an act which often

results in discomfort and further irritation. Non viscous creams and lotions require quick and dextrous application as they are inclined to flow off the site of treatment before penetration of the active agent is achieved. As a solution pharmaceuticals can be difficult to apply because they evaporate due to the heat of the skin surface before penetration to the affected site can be achieved. Mousses are well suited to the topical application of pharmaceuticals. Mousse formulations are typically formulated in a single or multiple phase liquid form and housed in a suitable container together with a propellant which facilitates the expulsion of the formulation from the container thus transforming it into a mousse or foam upon application. A mousse or foam formulation has physical characteristics which are dependent, at least in part, upon the choice and relative amounts of components such as solvents, propellants and surfactants which may be present. The combination of such components will determine the stability of the mousse which may retain its foam-like structure upon application or be "slow-breaking" or "quick breaking". This terminology relates to the behaviour of the foam towards shearing action as is sustained when the foam is rubbed into or spread over a surface onto which it has been dispensed. So-called "quick-breaking" mousses are formulated to minimise early evaporation upon application to the skin because of their viscous construction which nevertheless rapidly disintegrates upon spreading by the user. One beneficial characteristic of mousse vehicles is this semi-solid to solid nature of the foam matrix which allows the product to be applied with the hand in any orientation without the risk of run off. Although mousses can be water-based or hydroalcoholic, typically they are formulated with a high alcohol content which, upon application to the skin of a user, quickly evaporates driving the active agent through the upper skin layers to the site of treatment. It is thought that this action is a result of the defatting of the surface layers of the skin by the alcohol content of the mousse. Thus it is expected that an increase in the alcoholic content will have the effect of driving more active agent into the skin because of the increased defatting action of the alcohol present.

The Australian Patent 619256 to PARKE DAVIS PTY LTD and SOLTEC RESEARCH PTY LTD is directed to a vehicle which is formulated as a quick breaking mousse. In addition to the active agent and propellant, it has a quick breaking mousse vehicle including an aliphatic alcohol in an amount exceeding

40% w/w of the vehicle, water in amounts up to 40% w/w, a fatty alcohol in amounts less than 10% w/w and a surfactant in amounts of up to 15% w/w.

PCT/GB96/00490, a patent application in the name of MEDEVA PLC is also directed to a quick breaking mousse formulation for delivery of corticosteroids. This mousse also includes an aliphatic alcohol in the amount of 40% w/w or more, water in an amount of 10-40% w/w, fatty alcohol in the amount of up to 10% w/w and a surfactant in an amount of up to 15% w/w. A propellant is added compatible with the remainder of the vehicle.

PCT/AU98/00867, a patent application in the name of SOLTEC RESEARCH PTY LTD also describes a mousse vehicle for delivery of anti fungal active agents, particularly ketoconazole. The mousse vehicle of this application may be ethanolic or aqueous. One foamable composition according to this application includes up to 5% w/w long chain alcohols, up to 5% w/w quaternary compound, up to 10% w/w propylene glycol, up to 5% w/w active agent, up to 90% w/w lower alcohol solvent, up to 5% w/w surfactant, 5-95% w/w water and up to 20% propellant.

In relation to mousses it is generally accepted that high levels of alcohol are required to produce a single phase composition. Single phase compositions are desirable to obviate the need to disperse one phase within another prior to application of the mousse. This is conventionally done by shaking the product. In the absence of adequate shaking the active agent can be unevenly or inadequately dispersed through the composition, or can settle in one phase resulting in unsatisfactory application of the active agent to the site requiring treatment. Whilst the mousse formulation is widely accepted as a convenient form of application, high levels of alcohol are, however, commonly associated with skin irritation.

AU-A-21618/88, to RICHARDSON-VICKS, INC describes an anti acne solution which is hydroalcoholic in nature and additionally includes a taurate surfactant. The specification indicates that this formulation is especially effective in achieving penetration of the salicylic acid active agent to the stratum corneum, but does not facilitate penetration of the active through the skin into the general circulation.

In general terms, it is an object of this invention to provide a vehicle for percutaneous delivery of an active agent which is an alternative to those described in the prior art and which provides both high level penetration of the active agent to the site of treatment, and minimal penetration of the active agent past the skin into general circulation. It is a secondary object to provide a pharmaceutical composition suited to the treatment of acne which is cosmetically acceptable as well as being pharmaceutically effective.

Throughout the specification the term "vehicle" means a composition which has only excipients or components required to carry an active agent, but which itself has no pharmaceutical or therapeutic effect. The term "active agent" means a substance having a pharmaceutical, pharmacological or therapeutic effect in the absence of any excipient. A "pharmaceutical composition" is one having at least one active agent in a vehicle formulated to deliver the active agent to the site of treatment. The term "comprises/comprising" when used in this specification is taken to specify the presence of stated features, integers steps or components but does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.

SUMMARY OF THE INVENTION

To this end there is provided a hydroalcoholic vehicle for percutaneous delivery of an active agent to the epidermis, said vehicle comprising lower alcohol, water and wax-surfactant.

Throughout this specification the term "wax-surfactant" means a substance which is a wax also having surfactant properties, a surfactant also having wax properties, a combination of a wax and a surfactant or a substance having both wax and surfactant properties.

The invention is predicated upon the observation that the vehicles of the invention allow the penetration of surprisingly large quantities of active agent to the epidermis. In trials, skin models treated with vehicles according to the invention show receptor fluid having similar concentrations of active agent as prior art formulations, and also show that the rate of transferral of active agent into the epidermis appears the same as for prior art compositions. However, the higher concentration of active agent observed in the epidermis suggests that greater quantities of active agent are made available for transferral from the vehicle

according to the invention by virtue of its novel formulation. It is postulated that as the volatile component of the vehicle evaporates from the surface of the skin, the active agent is concentrated into the remaining non-volatile excipients. This increased concentration may lead to an increase in the diffusion rate of the drug into the skin. It is thought that the role of the wax-surfactant is to decrease the tendency of the drug to precipitate out of solution when the evaporation process has gone so far that the concentration of drug exceeds solubility in the remaining phase. Thus a high level of diffusion occurs as a result of the supersaturated state of the formulation remaining on the skin surface. It is also observed that the vehicle according to the invention has surprisingly low alcohol levels when compared to prior art formulations of this type. In particular, in formulations containing such low levels of alcohol it would be expected that the active agent would prematurely precipitate onto the surface of the skin limiting the quantity available for penetration. In the formulations of the invention it is observed that this premature precipitation does not occur. One advantage of such low levels of alcohol is the decreased level of skin irritation that may result when compared to prior art formulations.

The wax-surfactants utilisable in the vehicles according to the invention may be but are not limited to one or a combination of compounds having characteristics as defined hereinabove in respect of the term "wax-surfactant", and which are selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants. More preferably, the wax surfactant is one, or a combination of compounds selected from the group of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. Other suitable wax-surfactants maybe identified by reference to standard texts such as for example the Surfactant Encyclopaedia (M.M. Rieger, Allured Publishing Corp, 1993).

In one preferred embodiment of the invention, the wax-surfactant may be a cetearyl alcohol/PEG-20 stearate product.

In a preferred embodiment of this aspect of the invention the lower alcohol may be present in amounts of 5-40%w/w and the water is present in amounts 5-95%w/w. The wax-surfactant may be present in amounts of 0.1-10.0%w/w. The lower alcohol is preferably ethanol but may also be isopropanol or any other
5 suitable lower alcohol.

In a further preferred embodiment the vehicle is formulated as a mousse and so desirably additionally comprises foaming agent, structuring agents and a propellant. Suitable foaming agents and propellants will be known to those skilled in the art but may include for example hydrocarbons, such as propane, butane
10 and isobutane, and halogenated hydrocarbons, such as dichlorodifluoro methane, dichlorotetrafluoro ethane, and mixtures thereof. Care should be taken to ensure that the propellant is compatible with each of the other components of the formulation. The structuring agent may be selected according to several criteria: it should be soluble within some or all of the formulation components, it should
15 perform the structuring function at a low concentration thereby leaving minimal post application residue on the skin of the user, it should be of acceptable pharmaceutical or cosmetic grade quality. Typically, structuring agents are soluble in organic solvents and have slight solubility in propellants allowing for partial precipitation of solid material hence imparting structure and stability to the
20 foam. Suitable structuring agents include but are not limited to one or more substances which are selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants. More preferably, the structuring agents is one, or a combination of compounds selected from the group of acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates,
25 alkylidibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. Other suitable structuring agents may be identified by reference to standard texts such
30 as for example the Surfactant Encyclopaedia (M.M. Rieger, Allured Publishing Corp, 1993). Wax surfactants according to the invention may also be suitable as structuring agents in this embodiment of the invention thereby having a dual role in this invention.

The vehicles may also include other excipients such as for example but not limited to buffering agents, preservatives, emollients, fragrance, and penetration enhancers.

5 In a second aspect of the invention there is provided a pharmaceutical composition comprising at least one active agent in a hydroalcoholic vehicle for percutaneous delivery of an active agent to the epidermis, said vehicle comprising lower alcohol, water and wax-surfactant.

10 The wax-surfactants utilisable in this aspect of the invention may be but are not limited to one or a combination of compounds having characteristics as defined hereinabove in respect of the term "wax-surfactant", and which are selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants. More preferably, the wax surfactant is one, or a combination of compounds selected from the group of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl
15 isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. Other suitable wax-surfactants maybe identified by
20 reference to standard texts such as for example the Surfactant Encyclopaedia (M.M. Rieger, Allured Publishing Corp, 1993).

In one embodiment of this aspect of the invention, the wax-surfactant may be a cetearyl alcohol/PEG-20 stearate product.

25 Pharmaceutical active agents commonly used to treat acne and other skin diseases which may be included in the compositions of this aspect of the invention include but are not limited to the therapeutic substances salicylic acid, isotretinoin, benzoyl peroxide, resorcinol, non-steroidal anti-inflammatory drugs such as ketoprofen, corticosteroids such as cortisone, antifungals, antibiotics for microbial infections and anti-psoriatics such as etrinate. It is common to also
30 include other substances such as anaesthetics such as lignocaine where necessary.

In a preferred embodiment of this aspect of the invention the lower alcohol may be present in amounts of 5-40%w/w and the water may be present in

amounts 5-95%w/w. The wax-surfactant may be present in amounts of 0.1-10.0%w/w. The lower alcohol is preferably ethanol but may also be isopropanol or any other suitable lower alcohol.

In a further preferred embodiment of this aspect of the invention the vehicle
5 is formulated as a mousse and so desirably additionally comprises a foaming agent, structuring agents and a propellant. Suitable foaming agents and propellants will be known to those skilled in the art. The structuring agents may be selected according to the criteria mentioned hereinabove. The compositions may also include other excipients such as for example but not limited to buffering
10 agents, preservatives, emollients, fragrance, and penetration enhancers.

In a third aspect of the invention there is provided a pharmaceutical composition for treatment of acne comprising salicylic acid in a hydroalcoholic vehicle for percutaneous delivery to the epidermis, said vehicle comprising lower alcohol, water and wax-surfactant.

15 The wax-surfactants utilisable in the vehicles according to the invention may be but are not limited to one or a combination of compounds having characteristics as defined hereinabove in respect of the term "wax-surfactant", and which are selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants. More preferably, the wax surfactant is one,
20 or a combination of compounds selected from the group of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters,
25 polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. Other suitable wax-surfactants maybe identified by reference to standard texts such as for example the Surfactant Encyclopaedia (M.M. Rieger, Allured Publishing Corp, 1993).

In one embodiment of this aspect of the invention the wax-surfactant is a
30 cetearyl alcohol/PEG-20 stearate product.

In a preferred embodiment of this aspect of the invention the lower alcohol may be present in amounts of 5-40%w/w and the water may be present in

amounts of 5-95%w/w. The wax-surfactant may be present in amounts of 0.1-10.0%w/w. The salicylic acid may be present in amounts of 1.0-10.0%w/w.

In a further preferred embodiment of this aspect of the invention the lower alcohol is preferably ethanol but may also be isopropanol or any other suitable
5 lower alcohol.

In a further preferred embodiment of this aspect of the invention the vehicle is formulated as a mousse and so desirably additionally comprises a foaming agent, structuring agents and a propellant. Suitable foaming agents and propellants will be known to those skilled in the art. The structuring agents may
10 be selected according to the criteria mentioned hereinabove. The compositions may also include other excipients such as for example but not limited to buffering agents, preservatives, emollients, fragrance, and penetration enhancers.

A preferred pH range of the salicylic acid containing pharmaceutical compositions according to the invention is 2.5-6.5.

15 One particularly preferred embodiment of this aspect of the invention is a salicylic acid mousse composition with the following parameters:

Component	% w/w
WATER	0.5 – 95%
SODIUM HYDROXIDE	0 – 3.0%
SALICYLIC ACID	1.0 – 10.0%
QUATERNIUM-52 (and) WATER	0.1 – 5.0%
ALCOHOL DENAT.	5.0 – 40.0%
PROPYLENE GLYCOL	0 – 10.0%
CETEARYL ALCOHOL (and) PEG-20 STEARATE	0.1 – 10.0%
FRAGRANCE	0.05 – 1.0%
PROPANE (and) BUTANE (and) ISOBUTANE	1.0 – 10.0%

In another aspect of the invention there is provided a method of treatment of acne comprising applying to the skin of a patient requiring such treatment an
20 effective amount of a pharmaceutical composition comprising salicylic acid in a hydroalcoholic vehicle for percutaneous delivery of an active agent to the epidermis said vehicle comprising lower alcohol, water and wax-surfactant.

The wax-surfactants utilisable in this embodiment of the invention may be but are not limited to one or a combination of compounds having characteristics as defined hereinabove in respect of the term "wax-surfactant", and which are selected from the group consisting of anionic surfactants, cationic surfactants and
5 non ionic surfactants. More preferably, the wax surfactant is one, or a combination of compounds selected from the group of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic
10 acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. Other suitable wax-surfactants maybe identified by reference to standard texts such as for example the Surfactant Encyclopaedia (M.M. Rieger, Allured Publishing Corp, 1993).

15 In one embodiment of this aspect of the invention, the wax-surfactant is a cetearyl alcohol/PEG-20 stearate product.

In a preferred embodiment of this aspect of the invention the lower alcohol may be present in amounts of 5-40%w/w and the water may be present in amounts of 5-95%w/w. The wax-surfactant may be present in amounts of 0.1-
20 10.0%w/w. The salicylic acid may be present in amounts of 1.0-10.0%w/w.

In a further preferred embodiment of this aspect of the invention the lower alcohol is preferably ethanol but may also be isopropanol or any other suitable lower alcohol.

In a further preferred embodiment of this aspect of the invention the
25 pharmaceutical composition is formulated as a mousse and so desirably additionally comprises a foaming agent, structuring agents and a propellant. Suitable foaming agents and propellants will be known to those skilled in the art. The structuring agents may be selected according to the criteria mentioned hereinabove. The compositions may also include other excipients such as for
30 example but not limited to buffering agents, preservatives, emollients, fragrance, and penetration enhancers.

A preferred pH range of the salicylic acid containing pharmaceutical compositions according to the invention is 2.5-6.5.

Also provided is the use of a vehicle according to the invention for the delivery of salicylic acid to the skin of a patient for the treatment of acne, said vehicle comprising lower alcohol, water and wax-surfactant. In one preferred
5 embodiment of this aspect of the invention, the wax-surfactant is a cetearyl alcohol/PEG-20 stearate product.

The wax-surfactants utilisable in this embodiment of the invention may be but are not limited to one or a combination of compounds having characteristics as defined hereinabove in respect of the term "wax-surfactant", and which are
10 selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants. More preferably, the wax surfactant is one, or a combination of compounds selected from the group of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts,
15 heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin. Other suitable wax-surfactants maybe identified by reference to standard texts such as for example the Surfactant Encyclopaedia
20 (M.M. Rieger, Allured Publishing Corp, 1993).

In one embodiment of this aspect of the invention, the wax-surfactant is a cetearyl alcohol/PEG-20 stearate product.

In a preferred embodiment of this aspect of the invention the lower alcohol may be present in amounts of 5-40%w/w and the water may be present in
25 amounts of 5-95%w/w. The wax-surfactant may be present in amounts of 0.1-10.0%w/w. The salicylic acid may be present in amounts of 1.0-10.0%w/w.

In a further preferred embodiment of this aspect of the invention the lower alcohol is preferably ethanol but may also be isopropanol or any other suitable lower alcohol.

30 In a further preferred embodiment of this aspect of the invention the vehicle is formulated as a mousse and so desirably additionally comprises a foaming agent, structuring agents and a propellant. Suitable foaming agents and propellants will be known to those skilled in the art. The structuring agents may

be selected according to the criteria mentioned hereinabove. The compositions may also include other excipients such as for example but not limited to buffering agents, preservatives, emollients, fragrance, and penetration enhancers.

A preferred pH range of the salicylic acid containing pharmaceutical compositions according to the invention is 2.5-6.5.

EXAMPLE 1

COMPARATIVE EXAMPLE

In order to determine the superior utility of vehicles and compositions according to the invention, the following salicylic acid mousse formulation according to the invention was prepared:

Component	% w/w	(Trade name)
WATER	58.22	Purified Water B.P.
SODIUM HYDROXIDE	0.58	Sodium Hydroxide N.F.
SALICYLIC ACID	2.00	Salicylic Acid U.S.P.
QUATERNIUM-52 (and) WATER	1.00	Dehyquart SP
ALCOHOL DENAT.	30.00	Dehydrated Alcohol U.S.P.
PROPYLENE GLYCOL	2.00	Propylene Glycol U.S.P.
CETEARYL ALCOHOL (and) PEG-20 STEARATE	1.00	Polawax GP200
FRAGRANCE	0.20	Fragrance A922906
PROPANE (and) BUTANE (and) ISOBUTANE	5.00	P45 Hydrocarbon Propellant

This formulation was manufactured according to the following protocol.

PRODUCTION OF AEROSOL BASE – ETHANOL PHASE

Check weigh Ethanol, transfer to a suitably sized mixing vessel and heat to 30°C. Add Dehyquart SP, Propylene Glycol and Polawax GP200, maintain at 30°C and stir until clear. Maintain between 25°C-30°C, correct for any loss of Ethanol and add Fragrance A922906. Mix until uniform.

PRODUCTION OF AEROSOL BASE – WATER PHASE

Check weigh Water, transfer to a suitably sized mixing vessel and warm to 50°C. Add Sodium Hydroxide and mix until dissolved. Add Salicylic Acid and mix until dissolved. Cool to between 25°C and 30°C.

5 FILLING AND GASSING OF AEROSOL CAN

Filter the Ethanol phase through 100 micron screen. Filter the Water Phase through 100 micron screen. Fill required weight of Ethanol Phase at 25°C-30°C into Can. Fill required weight of Water Phase at 25°C-30°C into Can. Place Valve onto filled Can and crimp. Gas Can with Propellant to required weight.

- 10 The aim of the present study was to determine and compare the in-vitro human epidermal penetration and retention of salicylic acid applied topically in two different formulations, one according to the invention and one according to the prior art.

MATERIALS**15 Salicylate Formulations**

1. Salicylate mousse formulation as set out hereinabove.
2. Neutrogena™ Clear Pore treatment formulated as 2% salicylic acid (active ingredient) in a base of purified water, PEG-32, PVM/MA Decadiene crosspolymer, sodium hydroxide and fragrance.

20 Human Epidermal Membrane

- Epidermal membranes were prepared from full-thickness abdominal skin from 3 female donors (1 (code 136) = 37 years, diffusion cells 1-4 and 13-16; 2 (code 143) = 30 years, diffusion cells 5-8 and 17-20; 3 (code 121) = 56 years, diffusion cells 9-12 and 21-24), obtained following abdominoplasty, using the
- 25 heat-separation method.

Other Reagents

All reagents used for the preparation of buffers were of analytical grade and HPLC grade solvents were used throughout for the analysis of salicylic acid.

TEST PROCEDURES**30 Formulation Release Studies**

Diffusion cells: Horizontal Franz -type glass cells, application area 1.3cm²
Membrane: Human epidermal membrane

- Receptor phase: PBS pH 7.4 + 4% bovine serum albumin @ 35°C
(approximately 3.5ml per cell see Table 1)
- Donor phase: Finite (approximately 5mg/cm²), unoccluded formulation
- 5 Duration: 24 hours with complete receptor phase removal and replacement @ 1, 2, 4, and 24hrs, and 500µl removal and replacement @ 8hr.
- Mass Balance: Salicylic acid remaining on the surface of the epidermis, within the first tape strip (designated 'unpenetrated'), within the epidermal membrane and the receptor cell determined at
- 10 24hrs.

At t=0 approx. 5mg/cm² of test formulation (Table 1) was added to the donor side of each cell (n=12 per formulation), using a round ended glass rod was gently wiped over the surface of the membrane to spread formulation as evenly as possible. Concentrations of salicylic acid in each of the samples (receptor

15 phase, remaining on epidermis (washed with 0.5ml 50:50 acetonitrile:distilled water), on first tape strip and within the epidermis) were determined by HPLC.

Table 1. Cell receptor volumes and Formulation application weights.

Salicylate Mousse			Neutrogena		
Cell No	Receptor Volume (ml)	Applied per cell	Cell No	Receptor Volume (ml)	Applied per cell
1	3.8	9 μ l	13	3.4	10 μ l
2	3.6	"	14	3.6	"
3	3.7	"	15	3.4	"
4	3.6	"	16	3.6	"
5	3.6	"	17	3.7	"
6	3.8	"	18	3.7	"
7	3.7	"	19	3.6	"
8	3.6	"	20	3.7	"
9	3.6	"	21	3.6	"
10	3.6	"	22	3.7	"
11	3.6	"	23	3.6	"
12	3.7	"	24	3.7	"
Mean \pm SD g applied/cell		0.0077 \pm 0.0005	Mean \pm SD g applied/cell		0.0078 \pm 0.0003

RESULTS

5 Membrane Release of Salicylic Acid

The cumulative amount of salicylic acid entering the receptor phase of each cell, adjusted for the variations in cell receptor volumes, with time is shown in Table 2. The mean data \pm SEM for each formulation is summarised in Figure 1.

Table 2. Cumulative concentration of salicylate in the receptor phase following 24 hours diffusion from the Salicylate Mousse and Neutrogena Gel.

Salicylate Mousse

Cumulative amount of salicylate (μg) in receptor phase					
Cell	1 hr	2 hr	4 hr	8 hr	24 hr
1	7.11	9.16	11.01	13.15	16.04
2	2.83	4.58	6.33	8.42	10.39
3	4.87	6.66	8.46	10.48	12.62
4	3.00	4.74	6.49	8.24	9.64
5	4.55	6.70	8.72	10.75	12.71
6	4.0	6.14	11.01	16.10	18.13
7	4.49	8.17	22.14	28.03	32.67
8	4.43	6.27	15.96	20.85	23.25
9	2.30	4.04	5.79	7.67	8.70
10	4.57	6.31	8.10	9.85	10.53
11	3.35	5.10	7.03	8.85	9.44
12	2.80	4.60	6.70	8.91	11.64
Mean \pm SD	4.02 \pm 1.30	6.04 \pm 1.54	9.81 \pm 4.82	12.61 \pm 6.20	14.65 \pm 7.91

5

Neutrogena

Cumulative amount of salicylate (μg) in receptor phase					
Cell	1 hr	2 hr	4 hr	8 hr	24 hr
13	2.61	4.71	6.63	9.86	12.84
14	2.16	4.27	6.91	10.09	13.25
15	2.45	4.59	7.45	10.79	14.32
16	8.54	11.36	14.65	18.61	22.37
17	2.70	5.00	7.46	10.40	12.73
18	5.08	7.64	10.33	13.30	16.15
19	2.47	4.52	6.90	9.61	11.42
20	5.73	8.13	10.55	13.45	16.13
21	2.35	4.46	7.06	9.94	12.51
22	2.43	4.39	6.62	9.27	11.72
23	2.07	3.96	5.90	8.29	10.67
24	1.80	3.86	5.95	8.54	10.64
Mean \pm SD	3.36 \pm 2.04	5.57 \pm 2.28	8.03 \pm 2.57	10.85 \pm 2.88	13.73 \pm 3.28




Figure 1. Comparison of the cumulative amount of salicylic acid entering the receptor phase from each of the formulations over the 24hr study period (µg) (Mean±SEM, n=12).

Mass Balance

The amount of salicylate (µg) and the percent of the applied dose remaining on the surface of the epidermal membrane, recovered from the first tape strip, remaining within the epidermis and receptor phase at 24hrs is shown in Table 3, together with calculation of the total estimated recovery of the applied dose.

Table 3. Cumulative amount (μg) and percent of applied dose of salicylate recovered at 24 hours from the surface (remaining formulation), tape strip (designated as unabsorbed), epidermis and receptor phase.

Salicylate Mousse

Cell	Amount of salicylate recovered									
	Surface		Tape-strip		Epidermis		Receptor		Total	
	μg	%	μg	%	μg	%	μg	%	μg	%
1	93.7	58.0	1.0	0.62	15.8	9.78	16.0	9.9	126.6	78.3
2	99.7	61.7	1.2	0.71	7.9	4.91	10.4	6.4	119.2	73.7
3	122.6	75.8	1.5	0.94	7.8	4.82	12.6	7.8	144.6	89.4
4	99.5	61.5	2.6	1.60	4.9	3.00	9.6	6.0	116.6	72.1
5	127.9	79.1	1.4	0.87	7.5	4.65	12.7	7.9	149.5	92.5
6	74.8	46.2	3.7	2.29	10.9	6.71	18.1	11.2	107.4	66.4
7	72.7	45.0	5.0	3.09	10.7	6.61	32.7	20.2	121.1	74.9
8	74.7	46.2	5.3	3.27	10.6	6.58	23.2	14.4	113.9	70.4
9	95.0	58.7	4.5	2.81	11.1	6.87	8.7	5.4	119.3	73.8
10	96.0	59.4	5.4	3.34	11.0	6.83	10.5	6.5	123.0	76.1
11	112.8	69.8	3.7	2.30	8.6	5.33	9.4	5.8	134.6	83.2
12	102.2	63.2	4.9	3.03	9.2	5.67	11.6	7.2	127.9	79.1
Mean	97.6 \pm	60.4 \pm	3.4 \pm	2.1 \pm	9.7	6.0 \pm	14.7 \pm	9.1 \pm	129.3	77.5 \pm
\pm SD	17.8	11.0	1.7	1.1	\pm 2.7	1.7	7.1	4.4	\pm 18.6	7.6

Table 3 cont.

Neutrogena Clear pore treatment										
Amount of salicylate recovered										
Cell	Surface		Tape-strip		Epidermis		Receptor		Total	
	μg	%	μg	%	μg	%	μg	%	μg	%
13	158.8	98.2	1.88	1.16	3.40	2.10	12.8	7.9	176.9	109.4
14	144.5	89.4	3.19	1.97	2.69	1.66	13.3	8.2	163.7	101.2
15	152.7	94.4	4.18	2.59	3.29	2.03	14.3	8.9	174.5	107.9
16	169.0	104.5	1.31	0.81	2.79	1.73	22.4	13.8	195.5	120.9
17	151.9	93.9	1.27	0.79	3.25	2.01	12.7	7.9	169.1	104.6
18	170.0	105.1	1.13	0.70	2.74	1.70	16.2	10.0	190.0	117.5
19	140.4	86.8	2.18	1.35	3.18	1.96	11.4	7.1	157.2	97.2
20	163.1	100.9	0.97	0.60	2.42	1.50	16.1	10.0	182.6	112.9
21	191.2	118.2	1.32	0.81	3.84	2.37	12.5	7.7	208.9	129.2
22	152.3	94.2	1.17	0.72	3.06	1.89	11.7	7.2	168.2	104.0
23	215.9	133.5	1.75	1.08	4.08	2.52	10.7	6.6	232.4	143.7
24	152.2	94.1	1.89	1.17	2.95	1.82	10.6	6.6	167.7	103.7
Mean	163.5	101.1	1.9 \pm	1.2 \pm	3.1 \pm	1.9 \pm	13.7 \pm	8.5 \pm	182.2	112.7
\pm SD	\pm 21.3	\pm 13.2	1.0	0.6	0.5	0.3	3.3	2.0	\pm 21.6	\pm 13.3

STATISTICAL ANALYSIS

- 5 Statistical analysis of the percent of the applied dose of salicylate accumulated in the receptor phase after 24 hours of diffusion indicated there is no statistically significant difference between the two formulations. Statistical analysis of the percent of the applied dose accumulated in the epidermis after 24 hours of diffusion indicated there is a statistically significant difference between the two
- 10 formulations. The means and probability values are shown in Table 4. Boxplots (Figures 2A and B) indicate that the product according to the invention results in amounts of salicylate in the receptor and epidermis following 24 hours of diffusion which are considerably more variable than those from the Neutrogena product.

Table 4. Probability values obtained by statistical analysis of the amount of salicylic acid released from the formulations into the receptor and the epidermis at 24 hours.

	Product	n	Mean	Std. Deviation	Std. Error Mean	t test	Mann Whitney U
% of applied dose assayed in receptor after 24 hours	Salicylate	12	9.06	4.38	1.27	t=0.41	U=58.5
	Mousse					df=22	
	Neutrogena	12	8.49	2.02	0.58	p=0.688	p=0.435
% of applied dose assayed in epidermis after 24 hrs	Salicylate	12	5.98	1.68	0.48	t=8.22	U=0
	Mousse					df=11.7*	
	Neutrogena	12	1.94	0.29	0.08	p<0.001	p<0.001

5

*unequal variances

Figure 2A:





Figure 2B:



Figures 2A And B Are boxplot representations of the amount of salicylate assayed following 24 Hours of diffusion in the receptor and epidermis respectively. The black line represents the median, the box the interquartile range (50% of the data points), the circles (outliners) are greater than 1.5 but less than 3 times the box length and the whiskers are the range excluding the outliners.

Figure 3A:





FIGURE 3B:



Figures 3A and 3B are histograms representing the distribution of salicylate within the epidermis following diffusion of the salicylate mousse according to the invention and the Neutrogena gel respectively over 24 hours.

CONCLUSIONS

1. Salicylate from the two formulations accumulated in the receptor phase over 24 hours to the same extent.
2. Salicylate from the mousse accumulated in the epidermis to a greater extent than from the Neutrogena gel.
3. The degree of spread in the data points from the mousse was greater than from the Neutrogena gel.

Examples 2 and 3 demonstrate alternative salicylate formulations according to the invention.

Example 2

Component	% w/w	(Trade name)
SODIUM HYDROXIDE	0.55	
WATER	46.55	
PROPYLENE GLYCOL	2.00	
CETEARYL ALCOHOL (and) PEG-20 STEARATE	2.50	Polawax GP200
QUATERNIUM-52 and WATER	1.00	Dehyquart SP
SALICYLIC ACID	2.00	
ETHANOL	40.00	Alcohol 100 HGF3
PRESERVATIVE	0.10	Nipastat
PRESERVATIVE	0.10	Germall II
PERFUME	0.20	LFC 38314
PROPANE/BUTANE	5.00	P45

5 Example 3

Component	% w/w	(Trade name)
WATER	59.10	
CETEARYL ALCOHOL and PEG 20 STEARATE	2.50	Polawax GP200
QUATERNIUM-52 and WATER	1.00	Dehyquart S.P.
SALICYLIC ACID	2.00	
PRESERVATIVE	0.10	Nipastat
PRESERVATIVE	0.10	Germall II
PERFUME	0.20	LFC 38314
ETHANOL	30.00	Alcohol 95 PGF6
PROPANE/BUTANE	5.00	P45

Example 4

The following study was conducted to demonstrate the utility in the preferred mousse formulations according to the invention of different wax-surfactants, and to identify the level at which the wax-surfactant could be incorporated in the preferred mousse formulations of the invention. A secondary benefit in the formulations of the invention wherein the preferred wax-surfactant is cetearyl alcohol/PEG-20 stearate is that it gives structure to the mousse and increases the mousse stability. Alternative wax-surfactants were therefore identified as preferably having, and being present in quantities so as to achieve, this secondary advantage.

PROCEDURES

Method of Manufacture

1. Preparation of the bulk ethanol aerosol base
15 Weigh Ethanol and transfer into a suitably sized beaker, then add Dehyquart and propylene glycol. Stir the solution and heat at 30°C.
Bulk ethanol base was also made without Dehyquart SP (Quaternium 52.)
2. Preparation of the bulk water aerosol phase
Weigh water and transfer to a suitably sized beaker
20 Add Sodium Hydroxide and mix until dissolved
Add Salicylic Acid, heat the solution to 50°C and mix until dissolved
3. Preparation of the ethanol phase (Formulations with Dehyquart)
Weigh the bulk ethanol aerosol base into a beaker, add the require amount of the wax, mix until dissolved at 30°C
- 25 4. Filling and Gassing of Aerosol Bottle (Formulations with Dehyquart)
Transfer ethanol phase to an aerosol bottle
Transfer water phase to the aerosol bottle
Seal the can
Add the Propellant P45

5. Filling and Gassing of Aerosol Bottle (Formulations without Dehyquart)

Add wax surfactant directly to aerosol bottle

Transfer ethanol phase (without Dehyquart) to the aerosol bottle

Transfer water phase to the aerosol bottle

5 Seal the can

Add the Propellant P45

FORMULATION INGREDIENTS

Two base formulations were used to examine the wax surfactants as shown in the following tables, 5 and 6.

10 Table 5: Formulations that contained Dehyquart SP and the wax surfactant

Item No.	Ingredient	Lot #	% w/w	Theoretical Mass Weighed (g)
Phase 1- Water phase				
1	Purified water		58.42	29.21
2	Sodium hydroxide	13203	0.58	0.29
3	Salicylic acid	12911	2.00	1.00
Phase 2- Ethanol phase				
4	Ethanol 100AGF4	20102	30.00	15.00
5	Dehyquart SP	10665	1.00	0.50
6	Propylene Glycol	98599	2.00	1.00
7	wax		1.00	0.50
8	Fragrance A922906	98301	0.0	0.0
Phase 3				
9	Propellant P45		5	2.5
TOTAL			100.00	50.00

Table 6: Formulations that did not contain Dehyquart SP

Item No.	Ingredient	Lot #	% w/w	Theoretical Mass Weighed (g)
Phase 1- Water phase				
1	Purified water		58.42	29.21
2	Sodium hydroxide	13203	0.58	0.29
3	Salicylic acid	12911	2.00	1.00
Phase 2- Ethanol phase				
4	Ethanol 100AGF4	20102	31.00	15.50
5	Dehyquart SP	10665	0.00	0.00
6	Propylene Glycol	98599	2.00	1.00
7	Wax		1.00	0.50
8	Fragrance A922906	98301	0.0	0.0
Phase 3				
9	Propellant P45		5	2.5
TOTAL			100.00	50.00

A listing of the wax surfactants used in the formulation can be found in Table 7.

- Formulations containing 0.1%, 0.5%, 1.0%, 5.0%, 7.5% and 10.0% cetearyl alcohol/PEG-20 stearate were made based on the formulation in Table 5. As the level of wax-surfactant was modified from 1.0%, the water level was also modified, while keeping all other ingredients constant.

Mousse testing procedure

- After completing each formulation it was cooled to room temperature. The aerosol bottle was shaken, inverted and the product expelled from the nozzle. The mousse, if formed, was examined for at least 1 minute, and the physical appearance was noted.

The mousse was considered to be stable if the foam structure persisted for at least 1 min.

- A description of "good mouse" indicated a full foam with a fine bubble size and creamy to soft texture. Many formulations were initially a "good mouse" from the nozzle but then changed over time.

Results and discussion

Formulations with dehyquart

A small group of the wax surfactants were initially examined using the standard formulation that included Dehyquart (see Table 5). The results are listed in Table 7 and indicate that almost all produced an initial good mousse. Some of the foams subsequently broke to a liquid, though most of these were close to a stable mousse. After making a control without a wax surfactant, it was found that the Dehyquart (used as a rust inhibitor) also has good foaming properties, and results in a good mousse that breaks to a liquid in about 20 sec. To examine the foaming and stability properties of the wax surfactants it was necessary to proceed without the interference of the Dehyquart in the formulation.

Formulations without dehyquart

Dehyquart was removed from the formulation to allow a more thorough examination of the wax surfactants ability to both create and stabilise a foam. All of the wax surfactants were compared in the base formulation described in Table 6. These formulations were compared with a control that contained no wax (134/01/00), a Polawax formulation (134/01/15) and a formulation containing a liquid ethoxylated alcohol(134/02/14). The results are listed Table 7.

The control was expelled as a liquid, which simplified assessing the properties of the other formulations. The liquid surfactant is a good foam former and initially formed a good mousse, but it was not stable and broke to a liquid in 20-25 seconds. The Polawax formulation did not produce as good a mousse as when Dehyquart was also included but the foam was stable.

Therefore, a successful wax surfactant was described as producing a mousse in which a foam structure persisted for at least 1 min. If the formulation did not produce an initial foam, or the foam broke to a liquid in less than 30 sec, it was a clear failure. An intermediate group was also observed and was defined as those where the foam structure lasted for 30-60 sec.

Results are evident from table 7.

Table 7: Results of Wax surfactant performance in the Salicylic Acid Mousse. ✓ - stable mousse ≈ - Intermediate mousse x - no stable mousse

Formulation No	CTFA Name	Solubility in EtOH	Performance of the mousse		Performance of the mousse without Dehyquart in the formulation	
134/01/00	Control - no wax		Good mousse then quick break to liquid 20 sec		Immediate liquid	x
134/01/15	Cetearyl alcohol/PEG-20 stearate	Soluble	Good creamy mousse, very stable	✓	Flatter mousse with coarser bubbles, small expansion then stable	✓
134/01/14	Liquid Surfactant Non-ionic (Ethoxylated nonyl phenol)	Soluble	Good mousse then break to liquid 30-40 sec	≈	Good mousse then break to liquid 20-25 sec	x
134/02/20	Sodium hydrogenated tallow glutamate	Soluble			Good mousse then very quick collapse to stable thinner foam layer	✓
134/02/01	Palmitic Acid	Soluble			Stable flat foam on a liquid layer	≈
134/02/15	DEA Oleth-3 Phosphate	Soluble			Good mousse then slow expansion to coarse bubble then liquid 1 min	✓
134/02/16	Lecithin	Not soluble			Wet coarse mousse, very stable	✓
134/02/07	Cetearyl Alcohol, Dicapryl Phosphate (and) Ceteth-10 Phosphate	Soluble	Stable foam	✓	Out wet then stable foam forms, coarse bubbles	✓
134/02/11	Sodium Laureth Sulfate	Partially soluble			Good mousse then break to liquid 30 sec	≈
134/01/02	Ammonium lauryl sulfate	Soluble	Good mousse then very slow collapse	✓	Very quick break to liquid	x
134/02/23	Stearalkonium Chloride	Soluble			Good mousse then slow expansion to coarse bubble then liquid 50-60 sec	≈

Formulation No	CTFA Name	Solubility in EtOH	Performance of the mousse		Performance of the mousse without Dehyquant in the formulation	
134/02/08	Cetearyl Alcohol and Behentrimonium Methosulphate	Soluble	Stable foam	✓	Out wet then stable foam forms, coarse bubbles	✓
134/02/24	Cetearyl Alcohol	Soluble			Very good creamy mousse, very stable	✓
134/01/05	Stearyl Alcohol	Soluble	Good mousse then slow expansion to coarser bubble	✓	Partial mousse, very quick break to thin white layer on liquid	x
134/02/03	PEG-40 Stearate	Soluble	Stable foam	✓	Good mousse then slow expansion to coarse bubble then liquid 1-2 min	✓
134/01/07	PEG 20 Glyceryl Stearate	Soluble	Good mousse, slow expansion and wetter	✓	Good foam then slow expansion to coarser bubble, stable	✓
134/02/09	Glycol Stearate	Soluble	Fine mousse, collapsing in less than 30s	x	Flat coarse mousse, then slowly to large bubble then stable	✓
134/01/08	Glyceryl Stearate	Partially soluble	Sticky mousse, stable	✓	Precipitate interfered with nozzle, but partial stable mousse formed	✓
134/01/09	Polyglyceryl-3-Stearate	Partially soluble	Good mousse, quick break to large bubble then stable	✓	Very quickly expands to a large bubble, then stable	✓
134/01/10	Sucrose Stearate	Not soluble	Good mousse then rapid collapse to thinner layer stable foam	✓	Good mousse then slight collapse to stable foam	✓
134/02/06	Polysorbate 61	Soluble	-		Out wet then foam forms, slow expansion to liquid 2 min	✓
134/02/10	Sorbital Stearate	Soluble			Quick expansion to small layer large bubbles on liquid	≈

Formulation No	CTFA Name	Solubility in EtOH	Performance of the mousse		Performance of the mousse without Dehyquart in the formulation	
134/02/05	Ceteareth-20	Soluble	Stable foam	✓	Good mousse then very slow expansion to coarse bubble then liquid 5-10 min	✓
134/02/02	PEG-Lanolin	Soluble			Good mousse then very slow expansion to coarse bubble then liquid 5-10 min	✓

It will be appreciated that the scope of this invention extends beyond the specific embodiments detailed herein to hydroalcoholic formulations containing the unique combination of water/alcohol/wax-surfactants as hereinbefore set out in adjunct with low levels of alcohol. It will further be appreciated that the vehicles
5 and compositions of the invention as described provide advantages over the prior art both in terms of aesthetic characteristics and medical characteristics by virtue of the high levels of penetration achieved by the active agents.

CLAIMS:


1. A hydroalcoholic vehicle for percutaneous delivery of an active agent to the epidermis, said vehicle comprising lower alcohol, water and wax-surfactant, said wax surfactant as hereinbefore defined being one, or a combination of compounds selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants.
2. A hydroalcoholic vehicle as claimed in claim 1, said wax-surfactant as hereinbefore defined being one or a combination of compounds selected from the group consisting of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin.
3. A hydroalcoholic vehicle as claimed in claim 1 or claim 2 wherein said lower alcohol is present in amounts of 5-40%w/w, water is present in amounts 5-95%w/w and said wax-surfactant is present in amounts of 0.1-10.0%w/w.
4. A hydroalcoholic vehicle as claimed in any one of claims 1 – 3 wherein said vehicle is formulated as a mousse and additionally comprises a foaming agent, structuring agent and propellant.
5. A hydroalcoholic vehicle as claimed in any one of claims 1-4 wherein said wax-surfactant is cetearyl alcohol/PEG-20 stearate.
6. A pharmaceutical composition comprising at least one active agent in a hydroalcoholic vehicle for percutaneous delivery of the at least one active agent to the epidermis, said vehicle comprising lower alcohol, water and wax-surfactant, said wax surfactant as hereinbefore defined being one, or a combination of compounds selected from the group consisting of anionic surfactants, cationic surfactants and non ionic surfactants.

7. A pharmaceutical composition as claimed in claim 6, said wax-surfactant being one, or a combination of compounds selected from the group consisting of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin.
8. A pharmaceutical composition as claimed in claim 6 or 7 wherein said active agent is selected from the group consisting of salicylic acid, isotretinoin, benzoyl peroxide, resorcinol, non-steroidal anti-inflammatory drugs such as ketoprofen, corticosteroids such as cortisone, antifungals, antibiotics for microbial infections and anti-psoriatics such as etrinete.
9. A pharmaceutical composition as claimed in any one of claims 6 – 8 wherein said composition is formulated as a mousse and additionally comprises a foaming agent, structuring agent and propellant.
10. A method of percutaneous treatment of acne comprising applying to the skin of a patient requiring such treatment an effective amount of a pharmaceutical composition comprising salicylic acid in a hydroalcoholic vehicle, said vehicle comprising lower alcohol, water and wax-surfactant, said wax surfactant as hereinbefore defined being one, or a combination of compounds selected from the group of surfactants having wax-like properties and including acyl glutamates, phosphoric acids or salts, acyl isethionates, alkyl ether sulfates, alkyldibenzylmethylammonium salts, heterocyclic ammonium salts, tetraalkylammonium salts, ethoxylated carboxylic acids, ethoxylated glycerides, glycol esters, monoglycerides, polyglyceryl esters, polyhydric alcohol esters and ethers, sorbitan/sorbitol esters and ethoxylated alcohols including lanolin.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU01/01237

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : A61K 47/10, A61P 17/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K 47/10		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: IPC as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent WPAT: mousse/foam/aerosol/benzoyl peroxide/resorcinol/cortisone/nsaid/antifungal/isotretinoin/ alcohols/surfactant/emuls*/cetaryl*/PEG		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0331489 B1 (Parke Davis Pty. Ltd. and Soltec Research Pty. Ltd.) 7 July 1993. See the whole document	1 - 10
X	AU 709320 B2 (48851/96) (Medeva PLC) 23 September 1996. See the whole document.	1, 2, 4, 6 - 9
X	AU 701554 B2 (59115/96) (Taisho Pharmaceutical Co. Ltd.) 30 December 1996. See the whole document.	1 - 3, 6, 7
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 26 November 2001		Date of mailing of the international search report 30 NOV 2001
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  K.G. ENGLAND Telephone No : (02) 6283 2292

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU01/01237

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 747 021 A (Therman McKenzie, James Agard) 5 May 1998. See the whole document	1 - 3, 6 - 8
X	AU 732456 B2 (97288/98) (Soltech Research Pty. Ltd.) 10 May 1999. See the whole document	1 - 4, 6 - 9

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU01/01237

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member			
EP	331489	AU	30843/89	BR	8900962
		JP	2096522	NO	890899
		PH	25291	PT	89892
				IN	172749
				NZ	228188
				ZA	8901541
AU	709320	WO	9627376	AU	48851/96
		EP	813413	NZ	302727
		US	6126920	CA	2214436
		CZ	9702758	HU	9900801
				BR	9607687
				SK	1190/97
				CN	1179720
AU	701554	WO	9640121	EP	832649
		US	6001864	CA	2223747
		JP	9110690	JP	9110693
				CN	1188409
US	5747021	NONE			
AU	732456	WO	9920250	AU	97288/98
				EP	1024792
END OF ANNEX					

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.